Adcetris Could Be Curative in Some Patients with Refractory Hodgkin's

A phase II study of Adcetris in a traditionally difficult-to-treat patient population shows survival and cure potential.

According to the presentation made at the ASH meeting in December of 2013, about half of the patients in the trial diagnosed with relapsed or refractory Hodgkin’s lymphoma and treated with brentuximab vedotin in the study were alive at three years.

Ajay K. Gopal, MD, associate professor at the University of Washington, a member of Fred Hutchinson Cancer Research Center and director of clinical research in hematologic malignancies at the Seattle Cancer Care Alliance, told HemOncToday, "The most interesting finding is that about 10 percent of patients on this trial have been off therapy and are enjoying long-term remissions."

Studying the curative potential of Adcetris

The trial (median patient age, 31) tested Adcetris in 102 patients following an autologous stem cell transplantation (ASCT). Patients received a median of nine cycles of Adcetris.

The researcher gave the three-year survival rate as 54 percent, with 51 of 102 patients still alive after a median of 32.7 months from their first dose of Adcetris.

Furthermore, a full 18 patients are said to still be in remission by the standards of the investigators (that number dips to 14 per central independent review). Five of these patients received consolidative allogeneic stem cell transplantation, and nine received no additional treatment after Adcetris.

Those in remission tended to be younger in age and underwent more treatment cycles than those not in remission.

Regarding those patients and their remissions, Gopal said that it "raises the question that this agent may have curative potential in a subset of patients and sets the stage for formally evaluating this agent as part of initial therapy."

Source: HemOncToday

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...